Romulus K. Brazzell
Known title: CHIEF MEDICAL OFFICERCIK: 0001298079
Associated companies
Transaction History
| KALA | ▼ Sell | Open Market | 46,748 | $39K | 10/22/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 5,251 | $21K | 6/24/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 3,687 | $14K | 6/3/2025 | View on chart |
| KALA | ▲ Buy | Grant | 10,100 | $0 | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 2,446 | $19K | 1/6/2025 | View on chart |
| KALA | ▼ Sell | Open Market | 5,489 | $26K | 6/26/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 2,002 | $12K | 5/31/2024 | View on chart |
| KALA | ▲ Buy | Grant | 6,500 | $0 | 1/4/2024 | View on chart |
| KALA | ▼ Sell | Open Market | 1,617 | $11K | 1/4/2024 | View on chart |
| KALA | ▲ Buy | Grant | 49,356 | $0 | 6/22/2023 | View on chart |
| KALA | ▲ Buy | Grant | 17,916 | — | 5/31/2023 | View on chart |
| KALA | ▲ Buy | Grant | 12,800 | $0 | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 73 | $2K | 1/4/2023 | View on chart |
| KALA | ▼ Sell | Open Market | 261 | $2K | 10/26/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 3,144 | $1K | 6/27/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 3,504 | $5K | 1/4/2022 | View on chart |
| KALA | ▼ Sell | Open Market | 12,757 | $23K | 10/26/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
KALA Bio Signs LOI to Acquire Telehealth Platform
KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.
KALA Bio Signs LOI to Acquire Telehealth Platform. KALA Bio shares surged 57% after hours following the announcement of a non-binding letter of intent to acquire a nationwide telehealth platform. The target company has generated approximately $48 million in sales since inception. Additionally, the company signed a separate agreement to resell genetic testing products through a U.S. DNA testing platform.